ArticleNature2024
Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- PTEN-loss confers dependence on the guanylate synthesis enzyme IMPDH in T-cell acute lymphoblastic leukemia.EMBO molecular medicine · 2026Article
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- Nicotinamide Mononucleotide Adenylyltransferase 1 and NADMetabolites · 2026Review
- GDPPH1 induces cell cycle arrest by downregulation of CDK4/Cyclin D1 via the mCell death & disease · 2026Article
- Identification of hsa-miR-144-3p as a novel immunotherapeutic target for glioblastoma based on disulfidptosis-related analysis.Discover oncology · 2026Article
- USP5 regulates purine metabolism and represents a therapeutic target in esophageal cancer.Cell death & disease · 2026Article
- MBOAT1 Promotes Glioma Progression Through Enhancing Ferroptosis Resistance and Immunosuppressive Microenvironment.CNS neuroscience & therapeutics · 2026Article
- Coupling proteostasis andTheranostics · 2026Article
- PTEN-loss confers dependence on the guanylate synthesis enzyme IMPDH in T-cell acute lymphoblastic leukemia.bioRxiv : the preprint server for biology · 2025Article
- Beyond Cell Cycle Control:bioRxiv : the preprint server for biology · 2025Article
- IMPDH and GTP Metabolism in Cancer: Mechanisms, Regulation, and Translational Scope.Cancer science · 2025Review
- Adaptive nuclear GTP synthesis promotes glioblastoma treatment resistance and is a targetable vulnerability in patients.medRxiv : the preprint server for health sciences · 2025Article
- A Novel Allosteric Inhibitor Targeting IMPDH at Y233 Overcomes Resistance to Tyrosine Kinase Inhibitors in Lymphoma.Cancers · 2025Article
- Voltage-Gated sodium channel Nav1.6 mediates glioblastoma proliferation and migration via NaMolecular biology reports · 2025Article
- A Novel Class of Multi-substituted Diaryl Scaffold Derivatives Inhibit Glioblastoma Progression by Targeting CD155.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- IDENTIFICATION OF DISEASE-SPECIFIC VULNERABILITY STATES AT THE SINGLE-CELL LEVEL.bioRxiv : the preprint server for biology · 2025Article
- Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.Acta neuropathologica communications · 2025Review
- Beyond cell cycle control:Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Yu-Jung ChenLouis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Swathi V Iyer *Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5686-2978
David Chun-Cheng Hsieh *Tri-Institutional PhD Program in Chemical Biology, The Rockefeller University, New York, NY, USA.ORCID 0009-0003-0806-9555
Buren Li *Structure Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Harold K EliasImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tao WangCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jing LiBrain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mungunsarnai GanboldCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michelle C LienBrain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yu-Chun PengBrain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Xuanhua P XieCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-8032-4715
Chenura D JayewickremeCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marcel R M van den BrinkCity of Hope, Los Angeles, CA, USA.ORCID 0000-0003-0696-4401
Sean F BradyLaboratory of Genetically Encoded Small Molecules, The Rockefeller University, New York, NY, USA.ORCID 0000-0001-5967-8586
S Kyun LimKOBIOLABS, Inc., Seongnam-si, South Korea.
Luis F ParadaCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. paradal@mskcc.org.ORCID 0000-0003-2295-1432
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MProject 4: Secondary Cancers Among NF1 Cancer SurvivorsU54CA196519 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI David W Clapp, KEVIN M. SHANNON · 2015 to 2026
$26.9MIsolation, characterization and translational development of glioma stem cellsR35CA210100 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PARADA, LUIS FERNANDO · 2017 to 2023
$7.4MDiscovery of Antibiotics from Soil Microbiomes Using MetagenomicsR35GM122559 · NIGMS · ROCKEFELLER UNIVERSITY · PI SEAN F BRADY · 2017 to 2026
$4.7MNCI NIH HHS P30 CA008748NCI NIH HHS R35 CA210100NCI NIH HHS U54 CA196519NIGMS NIH HHS R35 GM122559
Abstract
Glioblastoma is incurable and in urgent need of improved therapeutics
Indexed as
Brain NeoplasmsGlioblastomaNiacinamideProdrugsTemozolomideAnimalsBlood-Brain BarrierCell Line, TumorCryoelectron MicroscopyFemaleGuanineHumansIMP DehydrogenaseMaleMechanistic Target of Rapamycin Complex 1MiceGuanineIMP DehydrogenaseIMPDH2, mouseMechanistic Target of Rapamycin Complex 1NADNiacinamideNicotinamide-Nucleotide AdenylyltransferaseProdrugsTemozolomide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.